About: Clearance and Persistence of SARS‐CoV‐2 RNA in COVID‐19 patients

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Clearance and Persistence of SARS‐CoV‐2 RNA in COVID‐19 patients Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Clearance and Persistence of SARS‐CoV‐2 RNA in COVID‐19 patients
Creator	Rodrigues, Fernando Pereira-Vaz, João Araújo, Lucília Camilo, Elisabete Carmo, Anália Coelho Da Silva, Andreia Correia, Lurdes Coucelo, Margarida Cunha, Elizabete Marques, Gilberto Martinho, Patrícia Mendes, Alexandra Morais, Célia Mota, Vanda Pereira, Janet Pinto, Catarina
Source	Medline; PMC
abstract	COVID‐19 patients may be discharged based on clinical resolution of symptoms, and evidence for viral RNA clearance from the upper respiratory tract. Understanding the SARS‐CoV‐2 viral clearance profile is crucial to establish a re‐testing plan on discharge and ending isolation of patients. We aimed to evaluate the number of days that a patient needed to achieve undetectable levels of SARS‐CoV‐2 in upper respiratory tract specimens (nasopharyngeal swab and/or an oropharyngeal swab). The clearance and persistence of viral RNA was evaluated in two groups of positive patients: those who achieved two negative RT‐PCR tests and those who kept testing positive. Patients were organized thereafter in two subgroups, mild illness patients discharged home and inpatients who had moderate to severe illness. Results from RT‐PCR tests were then correlated with results from the evaluation of the immune response. The study evidenced that most patients tested positive for more than two weeks and that persistence of viral RNA is not necessarily associated with severe disease but may result from a weaker immune response instead. This article is protected by copyright. All rights reserved.
has issue date	2020-06-02(xsd:dateTime)
bibo:doi	10.1002/jmv.26103
bibo:pmid	32484958
has license	no-cc
sha1sum (hex)	3c6419fba5fe2c4c422469939d12a63c531322f9
schema:url	https://doi.org/10.1002/jmv.26103
resource representing a document's title	Clearance and Persistence of SARS‐CoV‐2 RNA in COVID‐19 patients
has PubMed Central identifier	PMC7301002
has PubMed identifier	32484958
schema:publication	J Med Virol
resource representing a document's body	covid:3c6419fba5fe2c4c422469939d12a63c531322f9#body_text
is schema:about of	named entity 'COVID-19' named entity 'DISCHARGED' covid:arg/3c6419fba5fe2c4c422469939d12a63c531322f9 named entity 'based' named entity 'Persistence' named entity 'IgG' named entity 'virus' named entity 'correlation' named entity 'RT-PCR' named entity 'IgG' named entity 'viral RNA' named entity '8 days' named entity 'emergency department' named entity 'COVID-19 outbreak' named entity 'Centro Hospitalar e Universitário de Coimbra' named entity 'SARS-CoV-2' named entity 'immune response' named entity 'cross-sectional analysis' named entity 'nucleocapsid' named entity 'immune response' named entity 'IgG' named entity 'asymptomatic patients' named entity 'RT-PCR test' named entity 'tested positive' named entity 'IgG' named entity 'single-stranded RNA' named entity 'clinical virology' named entity 'incubation period' named entity 'SARS-CoV-2' named entity 'RNA' named entity 'induce the expression' named entity 'RT-PCR' named entity 'SARS-CoV-2' named entity 'viral RNA' named entity 'RNA' named entity 'immune response' named entity 'upper respiratory tract' named entity 'SARS-CoV-2' named entity 'viral RNA' named entity 'viral RNA' named entity 'pro-inflammatory' named entity 'viral RNA' named entity 'immune response' named entity 'quality control' named entity 'viral RNA' named entity 'antibody' named entity 'virus' named entity 'RNA' named entity 'Mann-Whitney' named entity 'IgM' named entity 'RT-PCR' named entity '69.8%' named entity 'viral RNA' named entity 'level of significance' named entity 'SARS-CoV-2' named entity 'coronavirus disease 2019' named entity 'RT-PCR' named entity 'gene' named entity 'Nasopharyngeal' named entity 'virus' named entity 'IgG antibodies' named entity 'serum samples' named entity 'nucleic acid' named entity 'virus' named entity 'titer' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software